Dr. Feuerstadt is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2200 Whitney Ave
Suite 360
Hamden, CT 06518Phone+1 203-281-4463Fax+1 203-287-2930
Education & Training
- Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Fellowship, Gastroenterology, 2007 - 2010
- New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2004 - 2007
- Weill Cornell MedicineClass of 2004
Certifications & Licensure
- CT State Medical License 2010 - 2025
- NY State Medical License 2006 - 2025
- FL State Medical License 2014 - 2016
- American Board of Internal Medicine Gastroenterology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- Stool Sample Collection Protocol for Development of Screening Test for Colorectal Cancer and Other Digestive Tract Cancers Start of enrollment: 2014 Oct 01
Publications & Presentations
PubMed
- 157 citationsACG Clinical Guideline: Epidemiology, Risk Factors, Patterns of Presentation, Diagnosis, and Management of Colon Ischemia (CI)Lawrence J. Brandt, Paul Feuerstadt, George F. Longstreth, Scott J. Boley
The American Journal of Gastroenterology. 2015-01-01 - 17 citationsAssessment of Quality of Life Among Patients With Recurrent Clostridioides difficile Infection Treated with Investigational Oral Microbiome Therapeutic SER-109: Second...Kevin W Garey, Jinhee Jo, Anne J Gonzales-Luna, Brittany Lapin, Abhishek Deshpande
JAMA Network Open. 2023-01-03 - 77 citationsSclerosing mesenteritis: a systematic review of 192 casesPrabin Sharma, Siddhartha Yadav, Christine Marie Needham, Paul Feuerstadt
Clinical Journal of Gastroenterology. 2017-02-14
Authored Content
- C. Difficile Infection at DDW 2023May 2023
Press Mentions
- VIDEO: Low Risk for Congestive Heart Failure Exacerbation with Zinplava for C. DifficileMay 15th, 2023
- Four Analyses of Data for REBYOTA™ (Fecal Microbiota, Live – Jslm), the First FDA-Approved Microbiome-Based Treatment for the Prevention of Recurrent C. Difficile Infection, Presented at DDW 2023May 8th, 2023
- Retrospective Analysis of Data Evaluating Safety and Efficacy of REBYOTA™ (Fecal Microbiota, Live – Jslm) in a Real-World Patient Population with Comorbidities and Risk Factors Published in Open Forum Infectious DiseasesMay 3rd, 2023
- Join now to see all
Professional Memberships
- Fellow
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: